Results
myelodysplastic syndromes
EVENT, MYELODYSPLASTIC SYNDROMES
The patients’ characteristics are presented in Supplementary Table 1. The 5-year DFS rate (95% confidence interval, 95%CI) was 36.0 (22.8–49.3)% in the OCV-501 group and 33.7 (20.2–47.8)% in the placebo group, indicating no significant difference (DFS We analyzed the effect of vaccination on peripheral (aNext, we analyzed the association between DFS and WT1-specific immunoreactivity. Enhanced WT1-specific IgG responses were observed in the OCV-501 group by the 25th week (Suppl. Figure 2) and this event was not related to age, sex, ECOG score, or myelodysplastic syndromes (MDS)-related changes (data not shown). Peak anti-OCV-501 IgG levels by the 25th week were correlated with the prognosis (The peak anti-OCV-501 IgG levels until the 25th week are correlated with prognosis. DFS (Although post-vaccination anti-OCV-501 IFNγ peak levels were also associated with DFS and OS (Fig. The peak OCV-501-specific IFNγ level correlates with prognosis. DFS (